Literature DB >> 19690896

[Long-term treatment with oral ketamine. Case report of a female patient with therapy-resistant post-herpetic neuralgia].

C Zimmer1, T A Treschan, S Meier, M Nosch.   

Abstract

Postherpetic neuralgia can lead to therapy-resistant neuropathic pain. We report the case of a 74-year-old woman with postherpetic perineal neuralgia resistant to opioids and antiepileptic drugs who has been successfully treated with oral ketamine for 28 months. Pain scores were reduced by more than 50%, despite dose reduction of other analgetic drugs. Significant side effects have not yet been reported. Despite "off-label" use, ketamine is an important third line option in cases of therapy-resistant neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19690896     DOI: 10.1007/s00482-009-0816-3

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  10 in total

1.  N of 1 randomised controlled trials of oral ketamine in patients with chronic pain.

Authors:  D R Haines; S P Gaines
Journal:  Pain       Date:  1999-11       Impact factor: 6.961

2.  Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report.

Authors:  K Fisher; N A Hagen
Journal:  J Pain Symptom Manage       Date:  1999-07       Impact factor: 3.612

3.  Side effects of ketamine in the long-term treatment of neuropathic pain.

Authors:  Petr Cvrcek
Journal:  Pain Med       Date:  2008-03       Impact factor: 3.750

Review 4.  Postherpetic neuralgia: irritable nociceptors and deafferentation.

Authors:  H L Fields; M Rowbotham; R Baron
Journal:  Neurobiol Dis       Date:  1998-10       Impact factor: 5.996

5.  Pharmacokinetics and analgesic effects of i.m. and oral ketamine.

Authors:  I S Grant; W S Nimmo; J A Clements
Journal:  Br J Anaesth       Date:  1981-08       Impact factor: 9.166

Review 6.  Ketamine in chronic pain management: an evidence-based review.

Authors:  Graham Hocking; Michael J Cousins
Journal:  Anesth Analg       Date:  2003-12       Impact factor: 5.108

7.  Successful treatment of postherpetic neuralgia with oral ketamine.

Authors:  V Hoffmann; H Coppejans; M Vercauteren; H Adriaensen
Journal:  Clin J Pain       Date:  1994-09       Impact factor: 3.442

8.  The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states.

Authors:  Clifford J Woolf; Stephen W N Thompson
Journal:  Pain       Date:  1991-03       Impact factor: 6.961

9.  Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia.

Authors:  Per Kristian Eide; Audun Stubhaug; Ivar Øye; Harald Breivik
Journal:  Pain       Date:  1995-05       Impact factor: 6.961

Review 10.  Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.

Authors:  Kathleen Hempenstall; Turo J Nurmikko; Robert W Johnson; Roger P A'Hern; Andrew S C Rice
Journal:  PLoS Med       Date:  2005-07-26       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.